PMID- 21704983 OWN - NLM STAT- MEDLINE DCOM- 20111121 LR - 20240318 IS - 1872-6240 (Electronic) IS - 0006-8993 (Print) IS - 0006-8993 (Linking) VI - 1404 DP - 2011 Aug 2 TI - Potential contribution of oxidative stress and inflammation to anxiety and hypertension. PG - 63-71 LID - 10.1016/j.brainres.2011.06.024 [doi] AB - Previously, we have published that pharmacological induction of oxidative stress causes anxiety-like behavior in rats and also is associated with hypertension in these animals. Here, we report that sub-chronic induction of oxidative stress via pharmacological induction leads to i) reduction in glyoxalase (GLO)-1 and glutathione reductase (GSR)-1 expression; ii) calpain mediated reduction of brain derived neurotrophic factor (BDNF) levels; iii) NFkappaB mediated upregulation of proinflammatory factors interleukin (IL)-6 and tumor necrosis factor (TNF)-alpha and elevated angiotensin (AT)-1 receptor levels in hippocampus, amygdala and locus coeruleus regions of the brain. Acute oxidative stress has opposite effects. We speculate that regulation of GLO1, GSR1, BDNF, NFkappaB and AT-1 receptor may contribute to anxiety-like behavior and hypertension in rats. CI - Published by Elsevier B.V. FAU - Salim, Samina AU - Salim S AD - Department of Pharmacological and Pharmaceutical Sciences, University of Houston, Houston, TX, USA. ssalim@uh.edu FAU - Asghar, Mohammad AU - Asghar M FAU - Taneja, Manish AU - Taneja M FAU - Hovatta, Iiris AU - Hovatta I FAU - Chugh, Gaurav AU - Chugh G FAU - Vollert, Craig AU - Vollert C FAU - Vu, Anthony AU - Vu A LA - eng GR - R03 AG029904/AG/NIA NIH HHS/United States GR - R03 AG029904-01A2/AG/NIA NIH HHS/United States GR - AG29904/AG/NIA NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural PT - Research Support, Non-U.S. Gov't DEP - 20110616 PL - Netherlands TA - Brain Res JT - Brain research JID - 0045503 RN - 0 (Brain-Derived Neurotrophic Factor) RN - 0 (Interleukin-6) RN - 0 (Receptor, Angiotensin, Type 1) RN - 0 (Tumor Necrosis Factor-alpha) RN - 1AVZ07U9S7 (Xanthine) RN - 5072-26-4 (Buthionine Sulfoximine) RN - EC 1.17.3.2 (Xanthine Oxidase) RN - EC 1.8.1.7 (Glutathione Reductase) RN - EC 3.4.22.- (Calpain) RN - EC 4.4.1.5 (Lactoylglutathione Lyase) SB - IM MH - Analysis of Variance MH - Animals MH - Anxiety/chemically induced/*pathology MH - Brain/*metabolism MH - Brain-Derived Neurotrophic Factor/metabolism MH - Buthionine Sulfoximine/adverse effects MH - Calpain/metabolism MH - Disease Models, Animal MH - Enzyme-Linked Immunosorbent Assay/methods MH - Gene Expression Regulation/drug effects/*physiology MH - Glutathione Reductase/metabolism MH - Hypertension/chemically induced/*pathology MH - Inflammation/*complications MH - Interleukin-6/metabolism MH - Lactoylglutathione Lyase/metabolism MH - Male MH - Oxidative Stress/drug effects/*physiology MH - Rats MH - Rats, Sprague-Dawley MH - Receptor, Angiotensin, Type 1/metabolism MH - Signal Transduction/drug effects MH - Time Factors MH - Tumor Necrosis Factor-alpha/metabolism MH - Xanthine/adverse effects MH - Xanthine Oxidase/adverse effects PMC - PMC3402065 MID - NIHMS306003 EDAT- 2011/06/28 06:00 MHDA- 2011/12/13 00:00 PMCR- 2012/08/02 CRDT- 2011/06/28 06:00 PHST- 2011/05/04 00:00 [received] PHST- 2011/06/01 00:00 [revised] PHST- 2011/06/09 00:00 [accepted] PHST- 2011/06/28 06:00 [entrez] PHST- 2011/06/28 06:00 [pubmed] PHST- 2011/12/13 00:00 [medline] PHST- 2012/08/02 00:00 [pmc-release] AID - S0006-8993(11)01128-0 [pii] AID - 10.1016/j.brainres.2011.06.024 [doi] PST - ppublish SO - Brain Res. 2011 Aug 2;1404:63-71. doi: 10.1016/j.brainres.2011.06.024. Epub 2011 Jun 16.